Latest News and Press Releases
Want to stay updated on the latest news?
-
ART5 is designed to address the most common root cause of ADPKD by targeting PKD1, potentially restoring PC1 production in approximately 85% of patientsFirst-in-human SAD study in healthy volunteers...
-
SAN DIEGO, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Arnatar Therapeutics, a biotechnology company pioneering RNA-based therapies for severe and underserved diseases, today announced that new preclinical...
-
SAN DIEGO, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Arnatar Therapeutics, a biotechnology company pioneering RNA-based therapies for severe and underserved diseases, emerges from stealth today and...